Warning: Illegal string offset 'otw_pm_portfolio_detail_1' in /home/forge/www.rel-lombardia.net/wp-content/plugins/portfolio-manager-lite/classes/otw_pm_dispatcher.php on line 144

Warning: Cannot assign an empty string to a string offset in /home/forge/www.rel-lombardia.net/wp-content/plugins/portfolio-manager-lite/classes/otw_pm_dispatcher.php on line 144

Warning: Illegal string offset 'otw_pm_portfolio_detail_2' in /home/forge/www.rel-lombardia.net/wp-content/plugins/portfolio-manager-lite/classes/otw_pm_dispatcher.php on line 144

Warning: Cannot assign an empty string to a string offset in /home/forge/www.rel-lombardia.net/wp-content/plugins/portfolio-manager-lite/classes/otw_pm_dispatcher.php on line 144

Warning: Illegal string offset 'otw_pm_portfolio_detail_3' in /home/forge/www.rel-lombardia.net/wp-content/plugins/portfolio-manager-lite/classes/otw_pm_dispatcher.php on line 144

Warning: Cannot assign an empty string to a string offset in /home/forge/www.rel-lombardia.net/wp-content/plugins/portfolio-manager-lite/classes/otw_pm_dispatcher.php on line 144

Warning: Illegal string offset 'otw_pm_portfolio_detail_4' in /home/forge/www.rel-lombardia.net/wp-content/plugins/portfolio-manager-lite/classes/otw_pm_dispatcher.php on line 144

Warning: Cannot assign an empty string to a string offset in /home/forge/www.rel-lombardia.net/wp-content/plugins/portfolio-manager-lite/classes/otw_pm_dispatcher.php on line 144

Warning: Illegal string offset 'otw_pm_portfolio_detail_5' in /home/forge/www.rel-lombardia.net/wp-content/plugins/portfolio-manager-lite/classes/otw_pm_dispatcher.php on line 144

Warning: Cannot assign an empty string to a string offset in /home/forge/www.rel-lombardia.net/wp-content/plugins/portfolio-manager-lite/classes/otw_pm_dispatcher.php on line 144

Warning: Illegal string offset 'otw_pm_portfolio_detail_6' in /home/forge/www.rel-lombardia.net/wp-content/plugins/portfolio-manager-lite/classes/otw_pm_dispatcher.php on line 144

Warning: Cannot assign an empty string to a string offset in /home/forge/www.rel-lombardia.net/wp-content/plugins/portfolio-manager-lite/classes/otw_pm_dispatcher.php on line 144

Warning: Illegal string offset 'media_type' in /home/forge/www.rel-lombardia.net/wp-content/plugins/portfolio-manager-lite/classes/otw_pm_dispatcher.php on line 154

Warning: Cannot assign an empty string to a string offset in /home/forge/www.rel-lombardia.net/wp-content/plugins/portfolio-manager-lite/classes/otw_pm_dispatcher.php on line 154
A phase 2, international, multicenter, randomized, open-label, parallel group study to evaluate the efficacy and safety of CC-486 (oral Azacitidine) alone and in combination with Durvalumab (MEDI4736) in subject with myelodysplastic syndromes who fail to achieve an objective response to treatment with Azacitidine for injection or Decitabine – Rete Ematologica Lombarda

Warning: Illegal string offset 'media_type' in /home/forge/www.rel-lombardia.net/wp-content/plugins/portfolio-manager-lite/skeleton/components/item_media.php on line 2

Project Description

Patologia MDS
Sponsor Celgene Corporation
Farmaco CC-486 e MEDI4736
Fase 2
Linea pazienti che non mostrano risposta al precedente trattamento con azacitidina iniettabile o decitabina.
 
Codice studio CC-486-MDS­006
Obiettivo primario L'endpoint primario di questo studio è il tasso complessivo di risposta obiettiva (ORR) al trattamento con CC-486 in monoterapia e con terapia combinata con CC-486 e durvalumab: proporzione di soggetti che raggiungono una risposta obiettiva (miglioramento ematologico [HI], risposta parziale [PR], remissione completa [CR] o CR del midollo) in base ai criteri modificati dell'International Working Group (IWG) 2006.
 
Responsabile della sperimentazione Prof. Fabio Ciceri, Ospedale San Raffaele Milano
Medici referenti Dr. Matteo Carrabba - Ospedale San Raffaele Milano
 
Data inizio dello studio 31 maggio 2017
Durata dello studio Data fine arruolamento prevista: giugno 2019
Stato del protocollo APERTO
 
Persona da contattare per l’invio di pazienti e modalità di contatto Prof. Fabio Ciceri, ciceri.clinicaltrials@hsr.it telefono: 0226434289
SCARICA LA SINOSSI DELLO STUDIO

Project Details